Multicenter Study Evaluating AI Assistance for Diagnosing and Managing Pancreatic Diseases Using Contrast-Enhanced CT Scans

What this Trial Is About

Researchers are evaluating an artificial intelligence AI system designed to assist in diagnosing and managing pancreatic diseases using contrast-enhanced CT scans. This study compares the AIs recommendations with those of experienced clinicians to assess the systems accuracy, safety, and usefulness in real clinical settings. The goal is to see if the AI can reliably classify patients, reduce missed malignant lesions, and prevent unnecessary surgeries, ultimately improving decisions for pancreatic conditions. The AI analyzes the CT images to classify patients into three groups Intervention for surgery or treatment, Intensive Surveillance close follow-up, or Routine Surveillance standard monitoring. Meanwhile, clinicians independently assess the same patients using the same categories. Patients in the Intervention group may undergo surgery or treatment, those in Intensive Surveillance receive personalized high-frequency follow-ups, and those in Routine Surveillance have standard follow-up for at least a year. If abnormalities develop, patients may be reclassified to a more intensive group. Participants undergo contrast-enhanced CT scans with their images analyzed by both AI and clinicians. Researchers track classification accuracy, agreement between AI and clinician decisions, rates of unnecessary surgeries, and missed malignant lesions over one year from the scan date. This helps determine the AI systems clinical value and safety. The study spans from March 2026 to October 2029 and includes adults aged 18 to 80 with suspected pancreatic disease.

AI-Powered Precision Decision-Making for Pancreatic Diseases